Norway Approves Public Funding for Ketamine Depression Treatment
Last reviewed and updated: June 26, 2026.
Key Takeaways
| Norway’s decision | Decision Making Forum approved generic IV ketamine for TRD — first country to fund generic (not just branded) ketamine under public healthcare |
| US contrast | IV ketamine is off-label for depression in the US — not covered by Medicare/Medicaid; Spravato (esketamine) is insured with prior auth for TRD |
| Australia TGA | Esketamine (Spravato) added to Pharmaceutical Benefits Scheme in 2023; Australia also world-first on clinical psilocybin/MDMA rescheduling (2023) |
| UK status | NICE approved esketamine (Spravato) for NHS coverage for TRD in 2022 — branded product only, not generic IV ketamine |
| What public reimbursement means | Removes out-of-pocket cost barrier ($400–$800/infusion in US); integrates treatment into standard psychiatric pathways rather than boutique clinics |
Norway has become the first country to provide national public funding for generic ketamine in treating treatment resistant depression. The Decision Making Forum for New Methods approved the groundbreaking decision during an early morning meeting, making the treatment available immediately across the European nation.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | Details |
|---|---|
| First of Its Kind | Norway becomes first country with national ketamine reimbursement for depression |
| Immediate Access | Treatment available now, including outpatient services |
| Universal Coverage | All appropriate patients can access IV ketamine regardless of location |
| Treatment Focus | Specifically targets treatment resistant depression cases |
| Government Body | Decision Making Forum for New Methods made the ruling |
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
A New Chapter in Mental Health Care
This decision transforms how Norway approaches severe depression cases. Patients who have failed multiple traditional treatments now have access to ketamine therapy through their public health system. The approval covers intravenous ketamine administration in both hospital and outpatient settings.
Consider what this means for someone who has tried numerous antidepressants without success. Previously, ketamine therapy remained expensive and largely inaccessible. Now these individuals can receive potentially life changing treatment regardless of their financial situation or geographic location within Norway.
Implications Beyond Norwegian Borders
The Norwegian model creates a template other nations may follow. Public health systems worldwide monitor such decisions carefully, particularly when they involve innovative psychiatric treatments. This approval could accelerate similar policies across Europe and beyond.
Mental health advocates have long argued for broader access to ketamine therapy. Research consistently shows its effectiveness for treatment resistant cases, yet cost barriers have limited its reach. Norway’s decision removes these obstacles entirely for eligible patients.
This development also signals growing acceptance of ketamine as legitimate psychiatric medicine rather than experimental treatment. The Norwegian government weighed extensive clinical evidence before reaching this conclusion, suggesting confidence in both safety and efficacy data.
See also: — our ketamine therapy resources.
Norway’s Decision in Global Context — What Public Reimbursement Actually Changes
Norway’s approval of generic ketamine for treatment-resistant depression under its national health system was the first decision of its kind globally, and its significance is more than symbolic. The Decision Making Forum for New Methods — Norway’s equivalent of NICE in the UK or CMS in the US — approved generic IV ketamine (not just esketamine/Spravato) for TRD, meaning patients can access the treatment through the public health system without paying out-of-pocket. This removes the principal barrier that has limited ketamine therapy uptake everywhere else: cost. In Norway, TRD patients who meet clinical criteria can now access infusion-based ketamine treatment the way they would access any other second-line antidepressant — through a prescription covered by the state. The operational implications are significant: clinics need not depend on patients who can afford $400–$800 per infusion out-of-pocket, and the treatment can be integrated into the standard psychiatric care pathway rather than remaining a boutique offering.
The generic vs. branded distinction matters enormously. Spravato (esketamine nasal spray), developed by Janssen/Johnson & Johnson, received FDA approval for TRD in 2019 and is covered under US insurance with prior authorization for appropriate patients — but it is the patented S-enantiomer of ketamine administered via nasal spray in certified healthcare settings. IV racemic ketamine, the far more common clinical formulation used in the US, is generic and off-label for depression. It is not covered by most US insurers precisely because the off-label designation gives payers cover to deny coverage. Norway’s decision to reimburse the generic IV formulation — rather than tying reimbursement to a specific branded product — is potentially more influential globally, because it demonstrates that regulatory and reimbursement frameworks can be built around the generic molecule, not just proprietary delivery vehicles. This is the model advocates for expanded US ketamine access have been pushing for.
Where other major markets stand. Australia’s Therapeutic Goods Administration approved intranasal esketamine (Spravato) in 2021 for TRD and major depressive disorder with acute suicidal ideation, and Australia’s Pharmaceutical Benefits Scheme added it in 2023 — making Australia the second country to offer publicly subsidized esketamine access, though still the branded product rather than generic IV ketamine. The UK’s NICE published a highly anticipated appraisal of esketamine (Spravato) in 2022 that approved it for TRD under NHS conditions — again the branded nasal spray. The US remains the notable holdout on any public coverage for IV ketamine, with Medicare and most Medicaid programs declining to cover it as an off-label use. The pattern is clear: countries are moving toward coverage, but most have so far followed the branded-product pathway rather than Norway’s generic approach.
The next wave: psilocybin as a reimbursement candidate. Norway’s ketamine decision arrived at a moment when psilocybin is beginning the same regulatory arc. Compass Pathways’ COMP360 (synthetic psilocybin) completed Phase 3 in 2025 with positive results in treatment-resistant depression, and a rolling NDA submission to the FDA began in late 2025. Australia’s TGA classified psilocybin and MDMA as Schedule 8 controlled medicines usable in approved clinical settings, effective July 2023 — a world-first rescheduling that made Australia the first country where psychiatrists can legally prescribe psilocybin for TRD and MDMA for PTSD. The question of whether public reimbursement will follow the same path it did for ketamine — branded approval first, generic/public coverage later — is the central access question for the next decade of psychedelic medicine. Norway’s willingness to take the generic route rather than waiting for a branded formulation may prove to be the more important precedent.
Frequently Asked Questions
What is generic ketamine vs. Spravato?
Ketamine is a molecule — specifically an NMDA receptor antagonist first approved as an anesthetic in 1970. “Generic ketamine” refers to off-patent racemic ketamine (a mixture of R- and S-enantiomers), which is the formulation used in most US ketamine infusion clinics. Spravato (esketamine) is a branded product developed by Janssen (a Johnson & Johnson company) — it contains only the S-enantiomer of ketamine, delivered via nasal spray in certified healthcare settings. Spravato received FDA approval specifically for treatment-resistant depression (2019) and major depressive disorder with acute suicidal ideation (2020), which means it can be covered by insurance with prior authorization for TRD patients. Generic IV ketamine, despite being used far more widely and having a substantial evidence base, is prescribed off-label for depression — and most US insurers decline to cover off-label use, leaving patients to pay $400–$800+ per infusion out of pocket.
Which countries cover ketamine therapy under public healthcare?
Norway is the first country to approve public reimbursement for generic IV ketamine for TRD, effective under its national health system’s Decision Making Forum approval. Australia’s Pharmaceutical Benefits Scheme covers Spravato (esketamine nasal spray) for TRD since 2023 — but this is the branded product, not generic IV ketamine. The UK’s NHS covers Spravato for TRD following a 2022 NICE approval — again, branded esketamine. Several European countries are at various stages of assessing esketamine for reimbursement. The United States does not cover IV ketamine under Medicare or most Medicaid programs due to its off-label status, though Spravato is covered under commercial insurance with prior authorization for qualifying TRD patients. Norway’s decision to cover the generic formulation rather than only the branded spray is internationally significant because it opens a different reimbursement pathway.
How does Norway’s ketamine reimbursement work?
Norway’s Nye Metoder (Decision Making Forum for New Methods) is the body that evaluates and approves new treatments for coverage under the Norwegian public health system. The forum approved generic ketamine for treatment-resistant depression — meaning patients who meet clinical criteria (typically failure of two or more antidepressant treatments) can access IV ketamine infusions as part of their publicly funded psychiatric care. The approval covers the generic molecule, not a specific branded product, which is what makes it distinct from Australia and the UK’s esketamine approvals. In practice this means Norwegian psychiatric hospitals and approved clinics can administer ketamine and bill the national health system, removing out-of-pocket costs for patients. The specific administration protocols and monitoring requirements are set by clinical guidelines, not the reimbursement decision itself.
Will the US ever cover IV ketamine under insurance?
The core obstacle in the US is the off-label designation: IV racemic ketamine is not FDA-approved for depression, which gives insurers strong grounds to deny coverage. The path to coverage would require either an FDA approval for IV ketamine (which would require a manufacturer to sponsor the trial, and because ketamine is generic there is limited commercial incentive to do so) or a policy change that allows CMS and private insurers to cover well-evidenced off-label uses for serious psychiatric conditions. Some advocates have proposed a similar Breakthrough Therapy designation or coverage pathway for generic IV ketamine analogous to what happened with Spravato. Norway’s decision adds to the international precedent base that supports such a push. The American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3) has been active in lobbying for coverage expansion. Progress is possible but would likely require Congressional or CMS action rather than FDA action alone.
